Trial
NCT01536067
Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Roswell Park Cancer Institute
Collaborators
National Cancer Institute (NCI); GlaxoSmithKline
Condition
Waldenström Macroglobulinemia
Intervention
ofatumumab
Why stopped
funding was withdrawn
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-06-10